Breaking News Instant updates and real-time market news.

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06

Axovant Phase 3 Alzheimer's study misses co-primary endpoints

Axovant Sciences announced that the Phase 3 Mindset clinical trial of its investigational drug intepirdine in patients with mild to moderate Alzheimer's disease who were receiving background donepezil therapy did not meet its co-primary efficacy endpoints. At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition or in measures of activities of daily living as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale and by the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale, respectively, compared to patients treated with placebo. In the study, intepirdine was generally well tolerated, the company added. After 24 weeks of treatment, change from baseline in cognition was non-significantly improved in the intepirdine arm versus the placebo arm. In addition, there was essentially no difference between the intepirdine and placebo arms in change from baseline in activities of daily living. Of the endpoints analyzed to date, the only endpoint in which any significant improvement was seen in the intepirdine arm versus the placebo arm was in the first key secondary endpoint, the Clinician Interview-Based Impression of Change plus caregiver interview, or CIBIC-plus. Axovant said, "The Company will work with investigators to conclude the MINDSET open-label extension study. " David Hung, CEO of Axovant, added, "While we are deeply disappointed by these trial results, we also are saddened for the millions of patients and families impacted by Alzheimer's disease. However, we believe that the fight against Alzheimer's and other important areas of unmet need in neurology is too important to be derailed by this setback.... We remain committed to advancing our pipeline." Axovant shares remain halted. They closed yesterday down 6c to $22.59.

AXON Axovant Sciences
$24.25

-0.74 (-2.96%)

07/10/17
JEFF
07/10/17
INITIATION
Target $40
JEFF
Buy
Axovant Sciences initiated with a Buy at Jefferies
Jefferies analyst Michael Yee initiated Axovant Sciences with a Buy and a $40 price target.
07/12/17
OPCO
07/12/17
NO CHANGE
OPCO
Outperform
Axovant Sciences upcoming results may drive valuation upside, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Axovant Sciences faces two substantial binary events including the Phase 3 MINDSET study results at the end of September and the Phase 2 HEADWAY study results in Q4. The combination of these two events could drive up to 100% valuation upside, he contends. Further, the analyst believes the company is positioned to deliver the first new symptomatic Alzheimer's Disease drug approved by the FDA in over a decade. Olson reiterates an Outperform rating on the shares.
09/08/17
EVER
09/08/17
NO CHANGE
Target $30
EVER
Outperform
Axovant Sciences assumed with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer assumed coverage on Axovant Sciences with an Outperform and a $30 price target.
09/14/17
JEFF
09/14/17
NO CHANGE
Target $40
JEFF
Buy
Axovant looks 'very intriguing' at $20 per share, says Jefferies
Jefferies analyst Michael Yee believes the recent selloff in shares of Axovant Sciences presents a "unique" buying opportunity. At around $20 per share, the stock looks "very intriguing," Yee tells investors in a research note. The analyst sees "significant" potential upside, to $40-$100 per share, if the Phase III Alzheimer's data this month is positive. Yee's downside case is $3-$10 per share on negative data. Investors "should and will" buy the large selloff on negative data because CEO David Hung is likely to pivot the company, bring in more assets, and create value "from there pretty quickly," the analyst contends. Yee has a Buy rating on Axovant with a $40 price target. He thinks the Phase III Alzheimer's data has a 50%-60% chance of being positive.

TODAY'S FREE FLY STORIES

MDT

Medtronic

$86.78

0.2 (0.23%)

, ISRG

Intuitive Surgical

$490.49

-5.17 (-1.04%)

05:25
06/18/18
06/18
05:25
06/18/18
05:25
Recommendations
Medtronic, Intuitive Surgical analyst commentary  »

Piper continues to…

MDT

Medtronic

$86.78

0.2 (0.23%)

ISRG

Intuitive Surgical

$490.49

-5.17 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

JD

JD.com

$43.63

-0.12 (-0.27%)

, GOOG

Alphabet

$1,151.95

-0.05 (-0.00%)

05:22
06/18/18
06/18
05:22
06/18/18
05:22
Hot Stocks
Google to invest $550M cash in JD.com as part of strategic partnership »

JD.com (JD) and Google…

JD

JD.com

$43.63

-0.12 (-0.27%)

GOOG

Alphabet

$1,151.95

-0.05 (-0.00%)

GOOGL

Alphabet Class A

$1,159.03

-1.08 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Oct

NVS

Novartis

$75.80

-0.19 (-0.25%)

05:20
06/18/18
06/18
05:20
06/18/18
05:20
Hot Stocks
Alcon AcrySof IQ PanOptix trifocal IOL shows superior performance in trial »

Alcon, the global leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYCEY

Rolls-Royce

$0.00

(0.00%)

05:20
06/18/18
06/18
05:20
06/18/18
05:20
Upgrade
Rolls-Royce rating change  »

Rolls-Royce upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASBFY

Associated British Foods

$0.00

(0.00%)

05:18
06/18/18
06/18
05:18
06/18/18
05:18
Upgrade
Associated British Foods rating change  »

Associated British Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACGL

Arch Capital

$80.43

-0.69 (-0.85%)

05:16
06/18/18
06/18
05:16
06/18/18
05:16
Initiation
Arch Capital initiated  »

Arch Capital initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNR

RenaissanceRe

$123.82

-0.33 (-0.27%)

05:15
06/18/18
06/18
05:15
06/18/18
05:15
Initiation
RenaissanceRe initiated  »

RenaissanceRe initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRB

W. R. Berkley

$75.33

0.06 (0.08%)

05:14
06/18/18
06/18
05:14
06/18/18
05:14
Initiation
W. R. Berkley initiated  »

W. R. Berkley initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RE

Everest Re

$226.37

0.38 (0.17%)

05:13
06/18/18
06/18
05:13
06/18/18
05:13
Initiation
Everest Re initiated  »

Everest Re initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$65.82

-0.17 (-0.26%)

05:13
06/18/18
06/18
05:13
06/18/18
05:13
Initiation
Arthur J. Gallagher initiated  »

Arthur J. Gallagher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$18.28

-0.52 (-2.77%)

05:12
06/18/18
06/18
05:12
06/18/18
05:12
Initiation
Kiniksa initiated  »

Kiniksa initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

GSKY

GreenSky

$24.27

-0.18 (-0.74%)

05:11
06/18/18
06/18
05:11
06/18/18
05:11
Initiation
GreenSky initiated  »

GreenSky initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

, XPO

XPO Logistics

$113.89

2.225 (1.99%)

05:11
06/18/18
06/18
05:11
06/18/18
05:11
Hot Stocks
Nestle, XPO Logistics co-creating 638,000-square-foot distribution center in UK »

Nestle (NSRGY) and XPO…

NSRGY

Nestle

$0.00

(0.00%)

XPO

XPO Logistics

$113.89

2.225 (1.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPN

Global Payments

$117.51

-0.24 (-0.20%)

05:09
06/18/18
06/18
05:09
06/18/18
05:09
Downgrade
Global Payments rating change  »

Global Payments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVOP

EVO Payments

$22.98

0.95 (4.31%)

05:05
06/18/18
06/18
05:05
06/18/18
05:05
Initiation
EVO Payments initiated  »

EVO Payments initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$130.91

0.81 (0.62%)

05:04
06/18/18
06/18
05:04
06/18/18
05:04
Downgrade
Chubb rating change  »

Chubb downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$60.17

-0.585 (-0.96%)

05:02
06/18/18
06/18
05:02
06/18/18
05:02
Downgrade
Leidos rating change  »

Leidos downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDFN

Redfin

$24.00

-0.64 (-2.60%)

, ZG

Zillow

$65.24

0.45 (0.69%)

05:00
06/18/18
06/18
05:00
06/18/18
05:00
Downgrade
Redfin, Zillow rating change  »

Redfin downgraded to Sell…

RDFN

Redfin

$24.00

-0.64 (-2.60%)

ZG

Zillow

$65.24

0.45 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZG

Zillow

$65.24

0.45 (0.69%)

04:58
06/18/18
06/18
04:58
06/18/18
04:58
Downgrade
Zillow rating change  »

Zillow downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRG

Evergy

$52.75

0.8 (1.54%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Evergy management to meet with Wolfe Research »

Wolfe Utilities Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

MDT

Medtronic

$86.78

0.2 (0.23%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Medtronic management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

UPLD

Upland Software

$35.30

0.04 (0.11%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Upland Software management to meet with Craig Hallum »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 26

    Jun

NUVA

NuVasive

$55.27

0.49 (0.89%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
NuVasive management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

WMGI

Wright Medical

$25.83

-0.26 (-1.00%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Conference/Events
Wright Medical management to meet with Leerink »

Meeting to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

BR

Broadridge

$114.93

0.06 (0.05%)

, RRC

Range Resources

$15.96

-0.19 (-1.18%)

04:55
06/18/18
06/18
04:55
06/18/18
04:55
Hot Stocks
Breaking Hot Stocks news story on Broadridge, Range Resources »

Broadridge to replace…

BR

Broadridge

$114.93

0.06 (0.05%)

RRC

Range Resources

$15.96

-0.19 (-1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.